This is a summary of the article describing the EMPEROR-Reduced study of empagliflozin, which was published in the New England Journal of Medicine. Empagliflozin (brand name Jardiance®) is a new drug therapy for the treatment of chronic heart failure. Chronic heart failure is a long-term condition where the heart cannot pump enough blood around the body, leading to symptoms such as shortness of breath, fatigue and build-up of too much water in the body (fluid retention). It also increases the risk for premature deathThis Plain Language Summary of Publication article from Future Cardiology describes a study called EMPEROR-Reduced. The study investigated a medicine called empagliflozin (brand name Jardiance®) which is a new drug treatment for chronic heart failure. This study focused on people with reduced ejection fraction which is a type of heart failure where insufficient blood is pushed out of the heart muscle as it contracts.

Visit the Future Medicine site using the link to read the full article.

The original article on which this summary is based is called ‘Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure’ and was published in The New England Journal of Medicine. 

Visit the New England Journal of Medicine site using the link to read the article.